34 research outputs found
TOX3 mutations in breast cancer
TOX3 maps to 16q12, a region commonly lost in breast cancers and recently implicated in the risk of developing breast cancer. However, not much is known of the role of TOX3 itself in breast cancer biology. This is the first study to determine the importance of TOX3 mutations in breast cancers. We screened TOX3 for mutations in 133 breast tumours and identified four mutations (three missense, one in-frame deletion of 30 base pairs) in six primary tumours, corresponding to an overall mutation frequency of 4.5%. One potentially deleterious missense mutation in exon 3 (Leu129Phe) was identified in one tumour (genomic DNA and cDNA). Whilst copy number changes of 16q12 are common in breast cancer, our data show that mutations of TOX3 are present at low frequency in tumours. Our results support that TOX3 should be further investigated to elucidate its role in breast cancer biology.Breast Cancer Research Foundation grant; University of Cambridge; Cancer Research UK; Hutchison Whampoa Limited; NIHR Cambridge Biomedical Research Centre; Marie Curie Career Integration Grant; Cancer Research UK [16942]; National Institute for Health Research [NF-SI-0611-10154
Autosub Long Range 1500: A continuous 2000 km field trial
Long Range Autonomous Underwater Vehicles (LRAUVs) offer the potential to monitor the ocean at higher spatial and temporal resolutions compared to conventional ship-based techniques. The multi-week to multi-month endurance of LRAUVs enables them to operate independently of a support vessel, creating novel opportunities for ocean observation. The National Oceanography Centreâs Autosub Long Range is one of a small number of vehicles designed for a multi-month endurance. The latest iteration, Autosub Long Range 1500 (ALR1500), is a 1500 m depth-rated LRAUV developed for ocean science in coastal and shelf seas or in the epipelagic and meteorologic regions of the ocean. This paper presents the design of the ALR1500 and results from a five week continuous deployment from Plymouth, UK, to the continental shelf break and back again, a distance of approximately 2000km which consumed half of the installed energy. The LRAUV was unaccompanied throughout the mission and operated continuously beyond visual line of sight
New hyperekplexia mutations provide insight into glycine receptor assembly, trafficking, and activation mechanisms
Background: Hyperekplexia mutations have provided much information about glycine receptor structure and function. Results: Weidentified and characterized nine new mutations. Dominant mutations resulted in spontaneous activation, whereas recessive mutations precluded surface expression. Conclusion: These data provide insight into glycine receptor activation mechanisms and surface expression determinants. Significance: The results enhance our understanding of hyperekplexia pathology and glycine receptor structure-function. © 2013 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A
A novel ESR2 frameshift mutation predisposes to medullary thyroid carcinoma and causes inappropriate RET expression
Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received
Background
The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy.
Objective
To report outcomes according to treatment received in men in randomised and treatment choice cohorts.
Design, setting, and participants
This study focuses on secondary care. Men with clinically localised prostate cancer at one of nine UK centres were invited to participate in the treatment trial comparing AM, radical prostatectomy, and radiotherapy.
Intervention
Two cohorts included 1643 men who agreed to be randomised and 997 who declined randomisation and chose treatment.
Outcome measurements and statistical analysis
Analysis was carried out to assess mortality, metastasis and progression and health-related quality of life impacts on urinary, bowel, and sexual function using patient-reported outcome measures. Analysis was based on comparisons between groups defined by treatment received for both randomised and treatment choice cohorts in turn, with pooled estimates of intervention effect obtained using meta-analysis. Differences were estimated with adjustment for known prognostic factors using propensity scores.
Results and limitations
According to treatment received, more men receiving AM died of PCa (AM 1.85%, surgery 0.67%, radiotherapy 0.73%), whilst this difference remained consistent with chance in the randomised cohort (p = 0.08); stronger evidence was found in the exploratory analyses (randomised plus choice cohort) when AM was compared with the combined radical treatment group (p = 0.003). There was also strong evidence that metastasis (AM 5.6%, surgery 2.4%, radiotherapy 2.7%) and disease progression (AM 20.35%, surgery 5.87%, radiotherapy 6.62%) were more common in the AM group. Compared with AM, there were higher risks of sexual dysfunction (95% at 6 mo) and urinary incontinence (55% at 6 mo) after surgery, and of sexual dysfunction (88% at 6 mo) and bowel dysfunction (5% at 6 mo) after radiotherapy. The key limitations are the potential for bias when comparing groups defined by treatment received and changes in the protocol for AM during the lengthy follow-up required in trials of screen-detected PCa.
Conclusions
Analyses according to treatment received showed increased rates of disease-related events and lower rates of patient-reported harms in men managed by AM compared with men managed by radical treatment, and stronger evidence of greater PCa mortality in the AM group.
Patient summary
More than 95 out of every 100 men with low or intermediate risk localised prostate cancer do not die of prostate cancer within 10 yr, irrespective of whether treatment is by means of monitoring, surgery, or radiotherapy. Side effects on sexual and bladder function are better after active monitoring, but the risks of spreading of prostate cancer are more common
Functional and quality of life outcomes of localised prostate cancer treatments (prostate testing for cancer and treatment [ProtecT] study)
Objective
To investigate the functional and quality of life (QoL) outcomes of treatments for localised prostate cancer and inform treatment decision-making.
Patients and Methods
Men aged 50â69âyears diagnosed with localised prostate cancer by prostate-specific antigen testing and biopsies at nine UK centres in the Prostate Testing for Cancer and Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) with concurrent androgen-deprivation therapy (ADT) and 77 low-dose-rate brachytherapy (BT, not a randomised treatment). Patient-reported outcome measures (PROMs) completed annually for 6âyears were analysed by initial treatment and censored for subsequent treatments. Mixed effects models were adjusted for baseline characteristics using propensity scores.
Results
Treatment-received analyses revealed different impacts of treatments over 6âyears. Men remaining on AM experienced gradual declines in sexual and urinary function with age (e.g., increases in erectile dysfunction from 35% of men at baseline to 53% at 6âyears and nocturia similarly from 20% to 38%). Radical treatment impacts were immediate and continued over 6âyears. After RP, 95% of men reported erectile dysfunction persisting for 85% at 6âyears, and after EBRT this was reported by 69% and 74%, respectively (Pâ<â0.001 compared with AM). After RP, 36% of men reported urinary leakage requiring at least 1âpad/day, persisting for 20% at 6âyears, compared with no change in men receiving EBRT or AM (Pâ<â0.001). Worse bowel function and bother (e.g., bloody stools 6% at 6âyears and faecal incontinence 10%) was experienced by men after EBRT than after RP or AM (Pâ<â0.001) with lesser effects after BT. No treatment affected mental or physical QoL.
Conclusion
Treatment decision-making for localised prostate cancer can be informed by these 6-year functional and QoL outcomes
Radiotherapy for Prostate Cancer: is it âwhat you doâ or âthe way that you do itâ? A UK Perspective on Technique and Quality Assurance
Recommended from our members
Investigating the fibroblast activation protein alpha expressing stromal cell in a spontaneous murine model of pancreatic adenocarcinoma
This thesis is not available on this repository until the author agrees to make it public. If you are the author of this thesis and would like to make your work openly available, please contact us: [email protected] Library can supply a digital copy for private research purposes; interested parties should submit the request form here: http://www.lib.cam.ac.uk/collections/departments/digital-content-unit/ordering-imagesPlease note that print copies of theses may be available for consultation in the Cambridge University Library's Manuscript reading room. Admission details are at http://www.lib.cam.ac.uk/collections/departments/manuscripts-university-archivesThere is evidence from cancer patients and animal models that the immune system is able to recognise cancer cells. It is unclear whether tumours escape this immune surveillance by selection of non-immunogenic variants in a Darwinian process termed cancer immunoediting, or by the recruitment of immune suppressive cells to the tumour microenvironment. This distinction is important as it informs the best means of cancer immunotherapy. Our lab has previously demonstrated that a stromal cell marked by fibroblast activation protein alpha (FAP) mediates local immune suppression in transplantable tumour models. Such models however do not always reflect the biology of human cancer. The following work investigates whether FAP+ cells modulate the immune response in a more physiological spontaneous murine model of pancreatic ductal adenocarcinoma (PDA). CD8+ T cells from PDA bearing mice show reactivity against thei.r own tumour cells in ELISpot assays, indicating an ongoing response to tumour antigens. Relieving immune suppression by depletion of FAP+ cells might therefore be effective in this model. Depletion of FAP+ cells for one week results in immune dependent arrest of PDA growth, demonstrating that FAP+ cells are a critical component of immune suppression. These data imply that immunoediting of tumour antigens does not account for escape from immune surveillance in this model. A therapy that targets FAP+ cell dependent immune suppression may allow an existing immune response to control cancers. Based on marker expression FAP+ cells in PDA appear related to carcinoma associated fibroblasts. Whilst it was previously thought that FAP+ cells were restricted to sites of inflammation and tissue remodelling, others in the lab have shown that FAP+ cells are widely distributed in normal tissues. FAP+ cells were sorted from PDA and several normal tissues for RNA-seq analysis. The transcriptomic data suggests that FAP+ cells in normal tissues are highly similar: FAP+ cells in PDA are related but form a distinct subset. Of particular interest, FAP+ cells from PDA and normal tissues express myeloid chemokines. FAP may therefore mark a lineage of tissue resident cells that regulate inflammation